The figure came in well above the $87.67 million analysts had been expecting heading into the report, according to consensus estimates. U.S. Amtagvi revenue reached approximately $91 million during the quarter, up 40% from the fourth quarter of 2025. Global sales of Proleukin, a supporting therapy used alongside Amtagvi treatment, contributed roughly $9 million and are expected to continue growing through the remainder of the year. Gross margin improved to 56% for the quarter, which the company attributed to higher Amtagvi sales volume, continued cost discipline and improving efficiency at its internal manufacturing operations. Total costs and expenses fell to $151.2 million from $173.7 million a year earlier, reflecting the combination of higher sales offsetting continued investment in research, development and commercial operations.